RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 2, 2010
Released June 2010

Featuring interviews with Drs Eric Van Cutsem, Jordan D Berlin, Andrew X Zhu and Eileen M O’Reilly. Special feature: Bonus web-only audio. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Colorectal cancer (CRC) is among the most common cancer types diagnosed in the United States, and its clinical management is continuously evolving. Although less frequently encountered individually, the collection of other “non-CRC” gastrointestinal (GI) tumors accounts for more per annum cancer-related deaths than tumors of the colon and rectum combined. Published results from ongoing trials lead to the emergence of new therapeutic agents and regimens, novel biomarkers influencing treatment selection and alterations to existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest scientific developments and expert perspectives, this CME activity assists medical oncologists with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Apply the results of emerging clinical research to the best-practice management of GI cancer originating within (CRC) and outside of (non-CRC) the colon and rectum.
    • Counsel patients with Stage II colon cancer about their individual risk of recurrence based on clinical, pathologic and genomic biomarkers, and consider adjuvant therapeutic options.
    • Formulate a treatment plan for patients with synchronous primary CRC and liver-only metastases.
    • Communicate the benefits and risks of existing and emerging anti-VEGF and anti-EGFR biologic therapy to patients with metastatic CRC.
    • Evaluate data on novel combination regimens for advanced pancreatic cancer.
    • Utilize clinical and molecular biomarkers to select optimal systemic treatment strategies for patients with gastric or gastroesophageal cancer.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with advanced hepatocellular cancer.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Prof Van CutsemPaid Research: Amgen Inc, Merck Serono, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr BerlinAdvisory Committee: Bristol-Myers Squibb Company; Consulting Agreements: Amgen Inc, Astellas Pharma US Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck and Company Inc, Roche Laboratories Inc, Schering-Plough Corporation; Paid Research: Amgen Inc, Genentech BioOncology, ImClone Systems Incorporated, OSI Oncology, Pfizer Inc. Dr ZhuAdvisory Committee: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Onyx Pharmaceuticals Inc. Dr O’ReillyConsulting Agreements: Bayer HealthCare Pharmaceuticals, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Genentech BioOncology, ImClone Systems Incorporated, Jennerex Inc, MediGene Inc, Merck and Company Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Polaris Group, Proacta Inc, Roche Laboratories Inc, Sanofi-Aventis; Paid Research: Amgen Inc, Astellas Pharma US Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Sanofi-Aventis.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2010
    Expiration date: June 2011

Acknowledge and close

Gastrointestinal Cancer Update, Issue 2, 2010
Released June 2010

Featuring interviews with Drs Eric Van Cutsem, Jordan D Berlin, Andrew X Zhu and Eileen M O’Reilly. Special feature: Bonus web-only audio. (Text and Audio Content)